Application Note

Sartobind® Rapid A: Comparable High Product Quality As Protein A Resins At High Productivity

Source: Sartorius
Feature 1

Processes to purify recombinant monoclonal antibodies (mAb) for therapeutic treatment are well established in the market. However, manufacturers are continuously improving their processes to lower patient risks and treatment costs.

The mAb capture step represents the current bottleneck in downstream processing. Protein A resins are diffusion-limited chromatography materials that require low flow rates to achieve a binding capacity above 30 g/L, which results in low productivity. Explore a novel chromatography membrane that combines high binding capacities with high flow rates for increased productivity while achieving comparable product quality as state-of-the-art protein A resins.

This novel technology increases productivity 10× compared to resins, which remains consistent during scale-up, and it purifies monoclonal antibodies with 10× less chromatography material used per batch, allowing for full utilization of the membrane within one batch. Plus, as a disposable consumable, it provides the opportunity to remove column handling in bioprocesses and resin reuse over multiple batches.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online